US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust SMID Growth Strength ETF

33.97

+0.23170.69%

Volume:155

Turnover:5K

Market Cap:32.27M

PE:- -

High:33.97

Open:33.74

Low:33.97

Close:33.74

52wk High:34.16

52wk Low:28.35

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.23

T/O Rate:0.02%

Dividend:0.01

Dividend Rate:0.03%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says

MT Newswires Live

EVEREST MED Secures Exclusive Asian Rights to Promising FSGS Treatment Candidate DMX-200

A Look At Travere Therapeutics (TVTX) Valuation After New Long Term FILSPARI FSGS Data

Simply Wall St.

Press Release: Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial

A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI’s Expanded FDA Approval In FSGS

Simply Wall St.

A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS

Simply Wall St.

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics (TVTX) Is Up 14.0% After FDA Focus Shifts To FILSPARI FSGS Label Expansion - Has The Bull Case Changed?

Simply Wall St.

Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed

Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program

Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference

Press Release: Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/FSGS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":33.9673,"timestamp":1787342400000,"preClose":33.7356,"halted":0,"volume":155,"delay":0,"changeRate":0.006868115581166589,"floatShares":950002,"shares":950002,"eps":0,"marketStatus":"Pre-Mkt","change":0.2317,"latestTime":"08-24 06:52:08 EDT","open":33.7356,"high":33.9673,"low":33.9673,"amount":5271,"amplitude":0,"askPrice":54,"askSize":100,"bidPrice":13.66,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":33.9673,"sharesOutstanding":950002,"nav":33.73,"aum":32043567.46,"dividendRate":0.0003,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.7356,"preClose":33.9673,"latestTime":"16:10 EDT","volume":6,"amount":203.6692,"timestamp":1787343004133,"change":-0.2317,"changeRate":-0.006821,"amplitude":0},"volumeRatio":0.2276733288436153},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":950002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.2276733288436153,"shares":950002,"dividePrice":0.0102,"high":33.9673,"amplitude":0,"preClose":33.7356,"low":33.9673,"week52Low":28.35,"pbRate":"--","week52High":34.155,"institutionHeld":0,"latestPrice":33.9673,"eps":0,"divideRate":0.0003,"volume":155,"delay":0,"ttmEps":0,"open":33.7356,"prevYearClose":30.4325,"prevWeekClose":33.9673,"prevMonthClose":32.5527,"prevQuarterClose":31.6297,"fiveDayClose":34.0354,"twentyDayClose":31.6355,"sixtyDayClose":30.855},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2026-06-25","symbol":"FSGS","amount":0.0102,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-25","defaultRemindTime":1782394200000,"name":"First Trust SMID Growth Strength ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-25","currency":"USD","dateTimestamp":1782360000000,"payDate":"2026-06-30"},{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"},{"executeDate":"2026-06-25","recordDate":"2026-06-25","paymentDate":"2026-06-30","value":0.0102,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644792742","title":"Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644792742","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644792742?lang=en_us&edition=fundamental","pubTime":"2026-06-17 11:08","pubTimestamp":1781665732,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) has added incremental value through its licensing deal with Everest Medicines while strengthening its funding position and validating DMX-200's commercial potential, Euroz Hartleys s","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","DXB.AU","FSGS","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126052833","title":"EVEREST MED Secures Exclusive Asian Rights to Promising FSGS Treatment Candidate DMX-200","url":"https://stock-news.laohu8.com/highlight/detail?id=1126052833","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126052833?lang=en_us&edition=fundamental","pubTime":"2026-06-16 11:19","pubTimestamp":1781579940,"startTime":"0","endTime":"0","summary":"The Chinese innovative pharmaceutical industry is currently transitioning from scale expansion to a new phase of high-quality competition centered on clinical value and supported by full industrial...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1161","DMX","FSGS","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641178458","title":"A Look At Travere Therapeutics (TVTX) Valuation After New Long Term FILSPARI FSGS Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2641178458","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641178458?lang=en_us&edition=fundamental","pubTime":"2026-06-07 09:21","pubTimestamp":1780795302,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) is back in focus after new long term data from its Phase 3 DUPLEX Study open label extension showed sustained, clinically meaningful proteinuria reductions in focal segmental glomerulosclerosis patients on FILSPARI.\nSee our latest analysis for Travere Therapeutics.\nThe latest DUPLEX data and recent licensing moves have arrived after a powerful run, with Travere’s share price up 58.07% over 90 days and a 1 year total shareholder return close to 3x, although short...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeutics-tvtx-valuation-after-new-long","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeutics-tvtx-valuation-after-new-long","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TVTX","BK4139","FFTY","FSGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242733","title":"Press Release: Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242733?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616060,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027. Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026. Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029. 30% reduction in uACR. In patients with severe focal segmental","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4604","FSGS","TM","BK4585","BK4007","BK4099","BK4555","MAZE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633493381","title":"Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633493381","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633493381?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  granted priority review to. Biologics License Application  for the accelerated approval of. atacicept in adult patients with IgA Nephropathy  with a. Prescription Drug User Fee Act  date of July 7, 2026. -- On track for U.S. commercial launch of atacicept in mid-2026, pending. -- Strong balance sheet expected to be sufficient to fund operations beyond. \"The team at Vera Therapeutics is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"During the first quarter, we made meaningful progress across key pre--commercial activities, including in sales, marketing, market access, compliance, and commercial operations, to support a successful U.S. launch, pending regulatory approval. We are excited for atacicept to potentially be the first approved drug targeting both BAFF and APRIL in IgAN patients.\". IgAN in adults, and assigned a PDUFA target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732799900.SGD","VERA","TACI","LU1074936037.SGD","BK4585","LU2347655156.SGD","LU0868494708.USD","BK4139","LU1069347547.HKD","BK4504","LABU","LU1585245621.USD","LU0868494617.USD","LU2279689827.SGD","LU1244550494.USD","BK4550","LU0726765562.USD","IE00BJTD4N35.SGD","LU0942090050.USD","LU0256863811.USD","BK4539","BK4588","LU2347655073.USD","LU0795875169.SGD","IE0004445015.USD","IE00BJJMRY28.SGD","IE00BFSS7M15.SGD","LU1732800096.USD","FSGS","LU0912757837.SGD","LU1430594728.SGD","LU2324357040.USD","MCD","LU1244550577.SGD","LU0417517546.SGD","BK4209","IE00BJTD4V19.USD","BK4610","IE00BFSS8Q28.SGD","BK4581","LU0795875086.SGD","LU1718418525.SGD","BK4534","LU1244550221.USD","LU2133065610.SGD","BK4566","IE00BJJMRX11.SGD","LU1035773651.USD","IE00B7KXQ091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453801","title":"Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453801","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453801?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Q1 2026 Vafseo (vadadustat) net product revenues grew to$15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289828/37519/en/Akebia-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Commercial-and-Pipeline-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","AKBA","BK4077","BK4183","IE00BLDYK493.USD","MACE","IE00BD6J9T35.USD","FSGS","BK4139","IE00B64QTZ34.USD","MI","LU2065731478.USD","RBC","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144963","title":"Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144963","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144963?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924860,"startTime":"0","endTime":"0","summary":"FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over year to $105 million. FDA approval in FSGS expands total addressable FILSPARI patient population in the U.S. to more than 100,000; first FSGS patients treated within one week of approval. First new patient dosed in restarted Phase 3 HARMONY Study of pegtibatinase; Topline data expected 2H 2027. Travere Therapeutics, Inc.  today reported its first quarter 2026 financial results and provided a corporate update.Research and development (R&D) expenses for the first quarter of 2026 were $57.1 million, compared to $46.9 million for the same period in 2025. The increase is primarily attributable to the restart of the Phase 3 HARMONY Study of pegtibatinase in classical HCU. On a non-GAAP adjusted basis, R&D expenses were $51.5 million for the first quarter of 2026, compared to $42.2 million for the same period in 2025.As of March 31, 2026, the Company had cash, cash equiva","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","TVTX","BK4007","BK4539","R","BK4022","FSGS","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630234053","title":"BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE","url":"https://stock-news.laohu8.com/highlight/detail?id=2630234053","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630234053?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:17","pubTimestamp":1777342620,"startTime":"0","endTime":"0","summary":"An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered  to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion. To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint. As previously announced, the FDA has agreed that proteinuria is an appropriate endpoint for full regulatory approval for DMX-200 in ACTION3. Evidence from the PARASOL working group, together with the recent FDA approval of an FSGS therapy in the US based on the proteinuria endpoint, further supports proteinuria as the prim","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/blinded-assessment-of-action3-statistical-assumptions-complete-302755001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7051","ARB.AU","BK7067","BK7508","BK7501","FSGS","DXB.AU","ARB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630494483","title":"Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630494483","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630494483?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:53","pubTimestamp":1777334008,"startTime":"0","endTime":"0","summary":"The latest update is out from Dimerix Limited ( ($AU:DXB) ). Dimerix has confirmed that its Phase 3 ACTION3 trial of DMX-200 in FSGS remains statis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-confirms-strong-statistical-power-and-refines-strategy-for-phase-3-fsgs-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-confirms-strong-statistical-power-and-refines-strategy-for-phase-3-fsgs-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4234","BK4084","FSGS","PW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630380533","title":"A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI’s Expanded FDA Approval In FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2630380533","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630380533?lang=en_us&edition=fundamental","pubTime":"2026-04-25 21:12","pubTimestamp":1777122720,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) just secured full FDA approval for FILSPARI in focal segmental glomerulosclerosis without nephrotic syndrome, extending its use beyond IgA nephropathy and reshaping how investors may think about the company’s rare kidney portfolio.\nSee our latest analysis for Travere Therapeutics.\nThe FDA decision arrives alongside a sharp 46.95% 1 month share price return and a 37.57% 3 month share price return, while the 1 year total shareholder return of 120.95% points to strong...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeutics-tvtx-valuation-after-filspari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeutics-tvtx-valuation-after-filspari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","FSGS","BK4139","LABU","TVTX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628790732","title":"A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2628790732","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628790732?lang=en_us&edition=fundamental","pubTime":"2026-04-18 17:06","pubTimestamp":1776503193,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) is in focus after the FDA granted full approval to FILSPARI to reduce proteinuria in adults and children with focal segmental glomerulosclerosis without nephrotic syndrome, the first authorized treatment for this rare kidney disorder.\nSee our latest analysis for Travere Therapeutics.\nThe FDA approval headlines arrive alongside strong price momentum, with a 7 day share price return of 40.78% and a 30 day return of 51.22%. The 1 year total shareholder return of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeutics-tvtx-valuation-after-fda-expa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeutics-tvtx-valuation-after-fda-expa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LABU","BK4588","TVTX","BK4585","FSGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627481974","title":"Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2627481974","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627481974?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:00","pubTimestamp":1776164400,"startTime":"0","endTime":"0","summary":"FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/14/3273192/0/en/Ligand-Partner-Travere-Therapeutics-Receives-Full-FDA-Approval-for-FILSPARI-sparsentan-in-FSGS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4585","BK4007","LENZ","LABU","BK4588","BK4139","FSGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579308","title":"Travere Therapeutics (TVTX) Is Up 14.0% After FDA Focus Shifts To FILSPARI FSGS Label Expansion - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579308","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624579308?lang=en_us&edition=fundamental","pubTime":"2026-04-02 15:29","pubTimestamp":1775114962,"startTime":"0","endTime":"0","summary":"Travere Therapeutics is drawing fresh attention after traders reacted to the upcoming April 13, 2026 FDA PDUFA decision on a supplemental filing for its rare kidney disease drug FILSPARI in focal segmental glomerulosclerosis, alongside a recent analyst upgrade to a Buy rating.\nThis combination of a potential label expansion in an area with limited treatment options and an improved analyst stance is sharpening focus on how central FILSPARI has become to Travere’s rare disease strategy.\nWe’ll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/travere-therapeutics-tvtx-is-up-140-after-fda-focus-shifts-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/travere-therapeutics-tvtx-is-up-140-after-fda-focus-shifts-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TVTX","FSGS","BK4585","BK4588","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622027703","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027703","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027703?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436400,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT. Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026. Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors. Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028. \"We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today's positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD,\" said Jason Coloma, Ph.D., chief executive officer of Maze. \"We look forward to advancing MZE829 into a pivotal program and to initiating our two Phase 2 trials of MZE782 in PKU and CKD. As we continu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4604","BK4555","BK4099","MAZE","BK4585","BK4007","FSGS","MIT","03160","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618505608","title":"Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2618505608","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618505608?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:38","pubTimestamp":1773095926,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix has completed enrolment and first dosing of the last adult patient in its pivotal ACTIO...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-over-recruits-in-pivotal-fsgs-phase-3-trial-as-last-adult-patient-dosed?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-over-recruits-in-pivotal-fsgs-phase-3-trial-as-last-adult-patient-dosed?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616085653","title":"Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2616085653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616085653?lang=en_us&edition=fundamental","pubTime":"2026-03-04 07:17","pubTimestamp":1772579845,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Dimerix Limited ( ($AU:DXB) ). Dimerix Limited has invited existing and potential investors to attend interacti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-courts-investors-with-perth-and-singapore-briefings-on-fsgs-phase-3-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-courts-investors-with-perth-and-singapore-briefings-on-fsgs-phase-3-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS","BK4211","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614005272","title":"Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005272","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005272?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:54","pubTimestamp":1772153679,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited will present an update on its Phase 3 ACTION3 trial of DMX-200 for FSGS k...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-to-showcase-phase-3-fsgs-program-at-oppenheimer-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-to-showcase-phase-3-fsgs-program-at-oppenheimer-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4585","HCSG","BK4588","LU0029874061.USD","XBI","LABU","BK4127","LU0128526141.USD","BK4581","BK4137","OPY","FSGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614404915","title":"Press Release: Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614404915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614404915?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109000,"startTime":"0","endTime":"0","summary":"-- Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy.  presented at American Society of Nephrology  Kidney Week and. -- U.S. Food and Drug Administration  granted priority review to. Biologics License Application  for atacicept with Prescription Drug. User Fee Act  date of July 7, 2026; potential commercial launch of. -- Strong balance sheet bolstered by equity and debt financings in 2025. expected to be sufficient to fund company beyond atacicept approval and. \"In 2025, Vera Therapeutics delivered on several key milestones as we advanced atacicept toward potential FDA approval and commercialization,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"The BLA has been granted priority review and we expect to be commercially prepared to successfully launch atacicept in IgAN in mid-2026 if approved. Our commercial team brings decades of experience launching innovative therapies and is eager to bring this potentially disease-modifying therapy to pa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4504","LU1074936037.SGD","LU1718418525.SGD","IE00B7KXQ091.USD","TACI","IE00BJJMRY28.SGD","LU0868494708.USD","LU1430594728.SGD","LU2347655073.USD","IE00BFSS7M15.SGD","LU1035773651.USD","LU0868494617.USD","LU2133065610.SGD","BK4585","MCD","BK4139","BK4539","IE00BJTD4V19.USD","LU1244550494.USD","IE0004445015.USD","BK4209","LU1069347547.HKD","LU0912757837.SGD","IE00BFSS8Q28.SGD","LU0795875169.SGD","VERA","LU1732799900.SGD","BK4550","IE00BJTD4N35.SGD","LU0256863811.USD","LU1585245621.USD","LU0417517546.SGD","LU0795875086.SGD","IE00BJJMRX11.SGD","BK4588","BK4610","BK4534","FSGS","LU0726765562.USD","LU0942090050.USD","LU1732800096.USD","LU2279689827.SGD","LU2347655156.SGD","LU1244550577.SGD","LU1244550221.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614504486","title":"Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2614504486","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614504486?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107200,"startTime":"0","endTime":"0","summary":"Q4 2025 net product revenues of$54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues  Expect significant Vafseo (va","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245436/37519/en/Akebia-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Commercial-and-Pipeline-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","AKBA","BK4161","IE00B64QTZ34.USD","LU2065731478.USD","BK4139","MACE","MI","RBC","BK4183","BK4157","USRC","IE00BLDYK493.USD","FSGS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}]}}